(89)Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma

Background: Despite the improvement in clinical outcomes for head and neck squamous cell carcinoma (HNSCC) as the result of cetuximab, patients may present with or develop resistance that increases tumor recurrence rates and limits clinical efficacy. Therefore, identifying those patients who are or...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Biother Radiopharm
Main Authors: Benedetto, Raquel, Massicano, Adriana V.F., Crenshaw, Bryant K., Oliveira, Renato, Reis, Rui M., Araújo, Elaine B., Lapi, Suzanne E.
Format: Artigo
Jezik:Inglês
Izdano: Mary Ann Liebert, Inc., publishers 2019
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6588098/
https://ncbi.nlm.nih.gov/pubmed/30865493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cbr.2018.2616
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki